SCHEMBL10102283

SCHEMBL10102283

CCc1cncc(OCc2ccccc2)c1C(=O)Oc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.45
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
P4HTM Q9NXG6 1/20 0.40
PTGER1 P34995 2/20 0.39
CA9 Q16790 1/20 0.39
MAOB P27338 2/20 0.39
BRD4 O60885 1/20 0.39
FOLH1 Q04609 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.38
HTT P42858 1/20 0.38
GFER P55789 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NR4A2 P43354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL112286 0.86 P4HTM (0.44) AOC3TSHRSMN1; SMN2P4HTMCA9
SCHEMBL10102300 0.86 TSHR (0.39) AOC3TSHRSMN1; SMN2P4HTMPTGER1
SCHEMBL113440 0.84 P2RX7 (0.45) AOC3TSHRSMN1; SMN2P4HTMPTGER1
SCHEMBL10102287 0.81 RXRA (0.43) TSHRPTGER1
SCHEMBL10101771 0.79 MAPT (0.42) TSHRSMN1; SMN2P4HTMPTGER1CA9
SCHEMBL10101770 0.77 MAPT (0.42) TSHRSMN1; SMN2P4HTMPTGER1MAPT
SCHEMBL290655 0.76 MAPT (0.41) TSHRSMN1; SMN2PTGER1MAOBMAPT
SCHEMBL10101772 0.75 MAPT (0.40) TSHRSMN1; SMN2P4HTMPTGER1CA9
SCHEMBL10107557 0.75 LMNA (0.44) TSHRSMN1; SMN2LMNAMAPTNPC1
SCHEMBL15065246 0.74 PARP10 (0.51) AOC3P4HTMBRD4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828988-B2 8-AZA tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2014-09-09 US disclosed
US-8367654-B2 8-AZA tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-20120108569-A1 8-AZA Tetracycline Compounds TETRAPHASE PHARMACEUTICALS, INC. 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108569-A1 8-AZA Tetracycline Compounds TET1, TET3, HDAC8 AOC3 4084/4885TSHR 1184/4885SMN1; SMN2 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.